Ascendis Health Limited

ASC

ZAE000185005

Pharmaceuticals

End-of-day quote Johannesburg S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
0.79 ^ZAR	-.--%		-2.47%	+1.28%

03-29	Ascendis Health Seeks Acquisitions	CI
03-28	Ascendis Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021

September 30, 2021 at 08:21 am

Ascendis Health Limited announced earnings results for the full year ended June 30, 2021. For the full year, the company announced sales was ZAR 2,229.085 million compared to ZAR 2,203.027 million a year ago. Operating loss was ZAR 450.460 million compared to ZAR 896.288 million a year ago. Net loss was ZAR 1,090.804 million compared to ZAR 965.808 million a year ago.

Latest news about Ascendis Health Limited

Ascendis Health Seeks Acquisitions	03-28	CI
Ascendis Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023	03-28	CI
Ascendis Health Limited Provides Earnings Guidance for the Six Months Ended 31 December 2023	03-26	CI
Ascendis Health Limited Announces Board Changes	03-25	CI
Ascendis Health Limited Announces Lawrence Mulaudzi Not Available for Re-Election as Director	11-29	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29	CI
Ascendis Health Limited Appoints Joseph Fine as Company Secretary	23-09-27	CI
Ascendis Health Flags Drop in FY23 EPS	23-09-26	MT
Ascendis Health Limited Provides Earnings Guidance for the Year Ended 30 June 2023	23-09-26	CI
Ascendis Health Advances Cost-cutting Program With New Auditor	23-04-06	MT
Ascendis Health Books Lower Fiscal H1 Attributable Profit	23-03-27	MT
Ascendis Health Terminates PricewaterhouseCoopers as Auditor	23-03-20	MT
South African Stocks End Tumultuous Week in the Red	23-03-17	MT
Ascendis Health Flags Lower EPS in Fiscal H1	23-03-17	MT
Ascendis Health Limited Appoints Bharti Harie as Chairman of the Board	22-12-08	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Transcript : Ascendis Health Limited, 2022 Earnings Call, Sep 28, 2022	22-09-28
Ascendis Health Limited Auditor Raises 'Going Concern' Doubt	22-09-26	CI
Ascendis Health Limited Announces Resignation of Richard Dawes an Independent Non-Executive Director	22-06-27	CI
Pharma-Q Holdings Ltd. and Imperial Logistics Limited cancelled the acquisition of Medicine Developers International/Pharmachem Pharmaceuticals/Alliance Pharma/Ascendis Pharma from Ascendis Health Limited.	22-06-26	CI
Ascendis Health Limited Announces Board Changes	22-06-13	CI
Ascendis Health Limited Announces Resignation of Gary Shayne as A Non-Executive Director	22-06-05	CI
Ascendis Health Limited Appoints Riyas Fadal as Chief Operating Officer	22-05-03	CI
Ascendis Health Seeks Acquisitions	22-02-18	CI

Chart Ascendis Health Limited

Duration

Period

More charts

Company Profile

Ascendis Health Limited specializes in developing, manufacturing and marketing care and health products. Net sales break down by family of products as follows: - pharmaceutical products (61.3%): primarily prescription drugs. The group also provides medical devices used in the radiology and surgery fields; - consumer products (31%): OTC medicines, vitamins and minerals, homeopathic products, ayurvedic products, sports nutrition products, functional foods, etc.; - care products for plants and animals (7.7%). Net sales are distributed geographically as follows: South Africa (71.3%), Cyprus (16%) and Romania (12.7%).

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASCENDIS HEALTH LIMITED	+1.28%	26.28M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals